SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

23 May 2023 Evaluate
The sales slipped to Rs. 194.55 millions for the March 2023 quarter as against Rs. 276.83 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -30.03 millions as compared to Net Loss of Rs. -152.35 millions of corresponding quarter ended March 2022The Operating Profit of the company witnessed a decrease to 33.46 millions from 122.22 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 194.55 276.83 -29.72 805.93 1643.49 -50.96 805.93 1643.49 -50.96
Other Income 6.15 6.60 -6.82 34.52 27.20 26.91 34.52 27.20 26.91
PBIDT 33.46 122.22 -72.62 190.52 1002.19 -80.99 190.52 1002.19 -80.99
Interest 28.13 29.10 -3.33 115.70 199.21 -41.92 115.70 199.21 -41.92
PBDT 3.94 65.09 -93.95 3.08 756.30 -99.59 3.08 756.30 -99.59
Depreciation 33.22 91.31 -63.62 135.16 153.89 -12.17 135.16 153.89 -12.17
PBT -29.28 -26.22 11.67 -132.08 602.41 -121.93 -132.08 602.41 -121.93
TAX 0.75 126.13 -99.41 0.78 203.38 -99.62 0.78 203.38 -99.62
Deferred Tax 4.23 126.13 -96.65 -1.29 203.38 -100.63 -1.29 203.38 -100.63
PAT -30.03 -152.35 -80.29 -132.86 399.03 -133.30 -132.86 399.03 -133.30
Equity 306.90 286.90 6.97 306.90 286.90 6.97 306.90 286.90 6.97
PBIDTM(%) 17.20 44.15 -61.04 23.64 60.98 -61.23 23.64 60.98 -61.23

Lyka Labs Share Price

57.60 1.05 (1.86%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×